NEWS HIGHLIGHTSMedia Articles Related to Brimonidine ( Ophthalmic)
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The 2009 Annual Meeting Of The American College Of Allergy, Asthma & Immunology (ACAAI)
Source: Allergy News From Medical News Today [2009.11.10]
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL. In a poster presentation titled, "Treatment of Ocular Itching with Bepotastine Besilate Ophthalmic Solution 1.
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The American College Of Clinical Pharmacy (ACCP) 2009 Annual Meeting
Source: Allergy News From Medical News Today [2009.10.22]
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.
Published Studies Related to Brimonidine ( Ophthalmic)
Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. [2009.09]
OBJECTIVE: To compare the efficacy of brimonidine, dorzolamide, and brinzolamide in reducing intraocular pressure (IOP) when used as adjunctive therapy to a prostaglandin analog (PGA)... CONCLUSIONS: The addition of brimonidine to a PGA provided greater IOP lowering than the addition of either dorzolamide or brinzolamide. Further studies are needed to evaluate the relative long-term efficacy and tolerability of these medications as adjunctive therapy to a PGA. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Purpose: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. [2008.04]
This paper aims to compare the efficacy and tolerability of timolol versus brimonidine in the treatment of glaucoma. Comprehensive searches were performed using Medline, Embase and the Cochrane Controlled Trials Register for randomized controlled trials comparing timolol and brimonidine... Brimonidine is associated with a higher rate of allergy.
Cyclosporine 0.05% ophthalmic preparation to aid recovery from loss of corneal sensitivity after LASIK. [2008.04]
PURPOSE: To determine whether cyclosporine (0.05%) can safely and effectively accelerate corneal nerve regeneration after LASIK, thereby facilitating faster recovery of corneal sensitivity... CONCLUSIONS: Cyclosporine was shown to significantly improve corneal sensitivity at 3 months after LASIK, which suggests that topical cyclosporine promotes enhanced corneal nerve regeneration.
Ocular Penetration and Pharmacokinetics of Topical Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions After Keratoplasty. [2008.04]
PURPOSE:: To compare the corneal and aqueous penetration and pharmacokinetics of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions and their effect on corneal reepithelialization after penetrating keratoplasty... CONCLUSIONS:: Topical preoperative moxifloxacin 0.5% achieved greater corneal and aqueous penetration than did gatifloxacin 0.3%. The clinical significance of this difference is not known. Postoperative use of these agents had similar effects on corneal reepithelialization.
Clinical Trials Related to Brimonidine ( Ophthalmic)
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Completed]
This study evaluates the safety and efficacy of brimonidine 0. 2%/timolol 0. 5% fixed
combination ophthalmic solution compared with concurrent brimonidine 0. 2% and timolol
ophthalmic solutions
Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs [Completed]
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and
brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy
(bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.
Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma [Completed]
Low-pressure (normal tension) glaucoma is a type of open-angle glaucoma resulting in damage
to the optic nerve and abnormalities of the visual field. Eye (intraocular) pressure in this
type of glaucoma is not higher than that usually considered to be normal (less than 21 mmHg)
for the eye. The present treatment of low-pressure glaucoma is also directed to lowering the
“normal” eye pressure. Both medications in this study, brimonidine and timolol, lower eye
pressure.
Laboratory research over the past decade indicates the potential to treat glaucoma not only
by lowering eye pressure, but with treatments aimed at the damage occurring at the optic
nerve. One group of drugs, selective alpha2-adrenergic agonists, have been shown in
laboratory animals to protect against the effects of nerve damage following local stroke.
Brimonidine, one of the medications in the current study, is a selective alpha2-adrenergic
agonist which protects against damage to optic nerve in animal models of glaucoma..
The hypothesis of the present study is that brimonidine eye drops provide protection to the
damaged optic nerve independent of lowering eye pressure in patients with low-pressure
glaucoma. This will be determined by (1) measuring eye pressure, (2) performing visual field
examinations, and (3) examination of the optic nerve.
Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients [Completed]
The purpose of this study is to obtain and assay human aqueous samples following
pre-operative dosing with 0. 1% Brimonidine Purite™ (pH 7. 8) or with 0. 15% Brimonidine Purite®
(pH 7. 2) from patients undergoing routine cataract surgery in order to evaluate the aqueous
concentration of the two formulations. Study hypothesis: The aqueous humor concentration 45
minutes following dosing of 0. 1% Brimonidine Purite™ (pH 7. 8) is comparable with 0. 15%
Brimonidine Purite® (pH 7. 2)
Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients [Completed]
|
